Article ID Journal Published Year Pages File Type
8790127 Urologic Oncology: Seminars and Original Investigations 2018 6 Pages PDF
Abstract
Determinants of aXRT delivery in stage III PC appear to be related to the proximity to community cancer centers and greater nodal burden. We find evidence of a survival benefit with the use of aXRT, particularly in those with higher nodal stage. Multi-institutional studies are needed to confirm these findings and improve treatment algorithms for high-stage PC.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , ,